Fig. 3

Effect of sorafenib and HGFK1 on proliferation of RCC cell lines Ketr-3, ACHN, 786-O, and normal renal tubular epithelial cells HK-2. Cell viability was determined with a CCK-8 assay Kit. a The cells were treated with rHGFK1 for 48 h at increasing concentrations (0, 0.5, 1, 2, 3, 4 μmol/l). rHGFK1 inhibited Ketr-3, ACHN, 786-O, and HK-2 cell growth with an IC50 of 1.2, 1.9, 2.0, and 8.7 μmol/l, respectively. b The cells were treated with sorafenib for 48 h at increasing concentrations (0, 1, 3, 6, 9, 12 μmol/l). Sorafenib inhibited Ketr-3, ACHN, 786-O, and HK-2 cell growth with an IC50 of 5.6, 5.0, 6.0, and 4.8 μmol/l, respectively. c Ketr-3 and ACHN cells were treated with sorafenib (6.0 μmol/l) and/or rHGFK1 (2.0 μmol/l) for 48 h. The IC50 values of each cell were calculated from dose-response curves using Graphpad prism 5.0. All data shown represent the mean ± SD from at least three independent experiments. Significant differences are denoted by *** for p < 0.001